Alpha Emitter Radium 223 in High-Risk Osteosarcoma: First Clinical Evidence of Response and Blood-Brain Barrier Penetration

JAMA Oncol. 2015 May;1(2):253-5. doi: 10.1001/jamaoncol.2014.289.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Blood-Brain Barrier / diagnostic imaging
  • Blood-Brain Barrier / metabolism*
  • Brain Neoplasms / diagnostic imaging
  • Brain Neoplasms / radiotherapy*
  • Brain Neoplasms / secondary*
  • Clinical Trials, Phase I as Topic
  • Femoral Neoplasms / pathology*
  • Femoral Neoplasms / therapy
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Multimodal Imaging
  • Osteosarcoma / diagnostic imaging
  • Osteosarcoma / radiotherapy*
  • Osteosarcoma / secondary*
  • Permeability
  • Positron-Emission Tomography
  • Radioisotopes / pharmacokinetics
  • Radioisotopes / therapeutic use
  • Radiopharmaceuticals / pharmacokinetics
  • Radiopharmaceuticals / therapeutic use*
  • Radium / pharmacokinetics
  • Radium / therapeutic use*
  • Time Factors
  • Tissue Distribution
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Radioisotopes
  • Radiopharmaceuticals
  • radium Ra 223 dichloride
  • Radium

Associated data

  • ClinicalTrials.gov/NCT01833520